Study wrapper · #473
Glucagonlike Peptide-1 (GLP-1) Receptor Agonists for Cardiometabolic Risk in Severe Mental Illness: A Narrative Review.
Editor's note
This narrative review evaluates GLP-1 receptor agonists as an add-on strategy for the cardiometabolic burden faced by people with severe mental illness on antipsychotics, drawing on nine studies including six randomised trials. The authors report that liraglutide and semaglutide were associated with meaningful weight reduction and improved glycaemic measures without worsening psychiatric symptoms, while the most common adverse events were mild-to-moderate gastrointestinal complaints. As a narrative review with a small underlying evidence base and short follow-up, it cannot establish long-term safety or durability in this population, and it does not pool data formally. For semaglutide readers, the useful signal is that in this vulnerable group the psychiatric-safety picture in short studies looked favourable, but the authors are explicit that larger, longer trials are needed before broad implementation.
Plain-language abstract
People with serious mental illness who take antipsychotic medicines often gain weight and develop metabolic problems. This review gathered nine studies, including six randomised trials, on whether GLP-1 medicines can help. Liraglutide and semaglutide were linked to meaningful weight loss and better blood-sugar control, and importantly did not appear to worsen psychiatric symptoms. The most common side effects were mild to moderate stomach and gut problems. Because the studies were small and short, the authors say it is too early to be sure about long-term safety, and they call for bigger, longer trials. Still, the early picture for semaglutide in this group looked encouraging.